iShares NASDAQ Biotechnology I...

NASDAQ: IBB
$107.74
-$1.10 (-1.0%)
Closing price March 31, 2020
On a company by company basis, investing in biotechs is somewhat tricky. However, there is an investment strategy that makes it much easier.
Chris Lange
24/7 Wall St. has picked a few of those standouts from Tuesday to highlight. We have included information about each company, as well as recent trading activity and the consensus price target.
Chris Lange
The 55th annual meeting of the American Society of Clinical Oncology (ASCO) is just around the corner. Biotech and pharmaceutical companies will descend on Chicago for a five-day all-out conference...
Chris Lange
Even though tech stocks on average are posting far better gains that health care stocks, a fair number of health care stocks — biotechs specifically — are blowing these tech stocks out of the...
Chris Lange
24/7 Wall St. has looked over some of the biotech sector's laggards, and we have also looked over the top exchange-traded funds for a breakdown of what they own to show how much they are lagging...
Jon C. Ogg
24/7 Wall St. has come up with its own view on earnings season by sector, along with relative performance on the top exchange traded funds for those sectors.
Jon C. Ogg
With 2018 coming to a close in just a few months, Merrill Lynch is taking a close look at the biotech industry and what key catalysts to expect before 2019.
Chris Lange
This year is shaping up to be a stellar one for biotech. Investors are looking for growth and upside, and that can drive the interest in biotechs ever higher.
Jon C. Ogg
Merrill Lynch believes that this could be the year biotechs break out. The firm has a few picks, bad and good, that it believes will play a big role in the coming year.
Chris Lange
Merrill Lynch singled out a group in the tech sector that the firm believes will outperform going forward -- specifically, internet stocks.
Chris Lange
The biotech industry has made a splash in 2017, outperforming practically all the broad markets. With this incredible display, it's no wonder that investor interest in this particular industry has...
Chris Lange
2016 was hard for biotech stocks, some more than others. These three present a buy low opportunity.
Mayer Winkler
Trump told Time that he wants to lower drug prices, a move that has hit the drug and biotech segments due to his comments.
Jon C. Ogg
We know that the broad markets work on the basis of greed and fear, but we have to ask ourselves whether we have become too afraid of Zika and when we can be greedy again.
Chris Lange
Here are four biotech companies that have just either closed fresh financing rounds or issued IPOs that exceeded price expectations.
Mayer Winkler